Skin Cancer Diagnosis and Management Continued
Photodynamic Therapy (PDT)For superficial BCCsCream on for 3 hoursIlluminate 7 to 9minutesRepeat after 1 to 3weeks80% cure...
PDT
Excisional Surgery
Mohs Surgery
Mohs Surgery
Squamous Cell CarcinomaIn Situ SCC (Bowens)Hyperkeratotic SCCKeratoacanthomaUlcerative SCCNodular (tumorous) SCCRecurrent ...
Squamous Cell CarcinomaMetastatic rate     (Rowe et al JAAD 1992) Literature review >12000 cases 2.3% if reviewed up to 5 ...
Metastatic Cutaneous SCC80%of metastases go to loco regional nodesTreatment protocols debated5yr survival 73% Sx and Xray ...
Squamous Cell CarcinomaBowens (In Situ SCC)   Well Differentiated Keratotic SCC   Ulcerated SCC                           ...
Squamous Cell CarcinomaUlcerated SCC   Tumorous SCCTumorous SCC    Tumorous SCC
Keratoacanthoma
Treatment OptionsEfudix/Aldara (In Situ SCC)Intralesional MTX, Bleo (KA)ExcisionRadiation Therapy
Pigmented Lesions and MelanomaBenign NaeviLesions with potential to develop melanoma             - dysplastic naevi       ...
Benign NaeviJunctional and Compound           naevi            Dermal Naevus    Halo Naevus               Blue Naevus
Potential for Melanoma                    Dysplastic Naevi                          HMFCongenital Naevus
Congenital Naevi          Melanoma RiskRisk for giant (>20cm) naevi is 5% – 7%by age 60Small (< 1.5cm) minimal riskInterme...
MelanomaIncidence   10684 new cases (2005)Deaths      1272 (2005)            (Australian Government DHA 2010)
Melanoma Clinical VariantsIn situSuperficial spreadingNodularLentigo maligna melanomaAmelanoticAcral lentiginousSubungal
MelanomaIn situ melanoma      Superficial Spreading                    Lentigo maligna melanoma Nodular
MelanomaAcral lentiginous melanoma    Amelanotic HMF                             Subungal Melanoma Amelanotic SSM
Differential DiagnosisDysplastic naevus   Ulcerated sccSeborrhoeic         Lentigo malignakerartosisDermatofibromaThrombos...
Melanoma DDDysplastic Naevi   In situ melanoma
Melanoma DDSuperficial BCC      Amelanotic Melanoma
Melanoma DDSeborrhoeic Keratoses
Melanoma DDDermatofibroma     Seborrhoeic keratosis
Melanoma DDApocrine hydrocystoma   Blue naevus
Melanoma DDPigmented BCC                 Pigmented solar keratosis
Melanoma DDSole of the foot eccrine spiradenoma   Ulcerated NMSC
Melanoma TreatmentIn situ at least 5mm margin<1mm at least 1 cm margin>1mm 2cm margin plus sentinal lymphnode biopsy option
Melanoma PrognosisIn situ    98 – 100%< 1mm      95%1 to 4mm   reducing with increased depth>4mm       50%Organ involvemen...
Melanoma follow upExamine surgical siteExamine lymph nodesFull skin exam for other melanomas3 months, 3 months, 6 months, ...
Miscellaneous Skin TumoursPyogenic granulomaKaposi’s Sarcoma
Miscellaneous TumoursPaget’s DiseaseExtramammaryPagets disease
Miscellaneous TumoursMerkel Cell TumourDermatofibrosarcomaprotruberans (DFSP)
Miscellaneous TumoursMetastatic TumourCutaneous lymphoma
Upcoming SlideShare
Loading in...5
×

4part2

402

Published on

4b

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
402
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Transcript of "4part2"

  1. 1. Skin Cancer Diagnosis and Management Continued
  2. 2. Photodynamic Therapy (PDT)For superficial BCCsCream on for 3 hoursIlluminate 7 to 9minutesRepeat after 1 to 3weeks80% cure rate
  3. 3. PDT
  4. 4. Excisional Surgery
  5. 5. Mohs Surgery
  6. 6. Mohs Surgery
  7. 7. Squamous Cell CarcinomaIn Situ SCC (Bowens)Hyperkeratotic SCCKeratoacanthomaUlcerative SCCNodular (tumorous) SCCRecurrent SCC
  8. 8. Squamous Cell CarcinomaMetastatic rate (Rowe et al JAAD 1992) Literature review >12000 cases 2.3% if reviewed up to 5 years (mostly in first 2 yrs) 5.2% if reviewed longer than 5 years (Range 0.1%to 9.9%)
  9. 9. Metastatic Cutaneous SCC80%of metastases go to loco regional nodesTreatment protocols debated5yr survival 73% Sx and Xray vs 54%Sxalone (Veness et al Laryngoscope 2005)
  10. 10. Squamous Cell CarcinomaBowens (In Situ SCC) Well Differentiated Keratotic SCC Ulcerated SCC Ulcerated SCC
  11. 11. Squamous Cell CarcinomaUlcerated SCC Tumorous SCCTumorous SCC Tumorous SCC
  12. 12. Keratoacanthoma
  13. 13. Treatment OptionsEfudix/Aldara (In Situ SCC)Intralesional MTX, Bleo (KA)ExcisionRadiation Therapy
  14. 14. Pigmented Lesions and MelanomaBenign NaeviLesions with potential to develop melanoma - dysplastic naevi - congenital naevi -lentigo maligna(HMF)Melanoma - in situ melanoma - superficial spreading melanoma - nodular melanoma - lentigo maligna melanoma - acral lentiginous melanoma
  15. 15. Benign NaeviJunctional and Compound naevi Dermal Naevus Halo Naevus Blue Naevus
  16. 16. Potential for Melanoma Dysplastic Naevi HMFCongenital Naevus
  17. 17. Congenital Naevi Melanoma RiskRisk for giant (>20cm) naevi is 5% – 7%by age 60Small (< 1.5cm) minimal riskIntermediate (1.5cm to 20cm) (debated)when it does it is usually after puberty
  18. 18. MelanomaIncidence 10684 new cases (2005)Deaths 1272 (2005) (Australian Government DHA 2010)
  19. 19. Melanoma Clinical VariantsIn situSuperficial spreadingNodularLentigo maligna melanomaAmelanoticAcral lentiginousSubungal
  20. 20. MelanomaIn situ melanoma Superficial Spreading Lentigo maligna melanoma Nodular
  21. 21. MelanomaAcral lentiginous melanoma Amelanotic HMF Subungal Melanoma Amelanotic SSM
  22. 22. Differential DiagnosisDysplastic naevus Ulcerated sccSeborrhoeic Lentigo malignakerartosisDermatofibromaThrombosedhaemangiomaPigmented bccSuperficial bcc
  23. 23. Melanoma DDDysplastic Naevi In situ melanoma
  24. 24. Melanoma DDSuperficial BCC Amelanotic Melanoma
  25. 25. Melanoma DDSeborrhoeic Keratoses
  26. 26. Melanoma DDDermatofibroma Seborrhoeic keratosis
  27. 27. Melanoma DDApocrine hydrocystoma Blue naevus
  28. 28. Melanoma DDPigmented BCC Pigmented solar keratosis
  29. 29. Melanoma DDSole of the foot eccrine spiradenoma Ulcerated NMSC
  30. 30. Melanoma TreatmentIn situ at least 5mm margin<1mm at least 1 cm margin>1mm 2cm margin plus sentinal lymphnode biopsy option
  31. 31. Melanoma PrognosisIn situ 98 – 100%< 1mm 95%1 to 4mm reducing with increased depth>4mm 50%Organ involvement <10% 5 yr survival
  32. 32. Melanoma follow upExamine surgical siteExamine lymph nodesFull skin exam for other melanomas3 months, 3 months, 6 months, 6 months then every year
  33. 33. Miscellaneous Skin TumoursPyogenic granulomaKaposi’s Sarcoma
  34. 34. Miscellaneous TumoursPaget’s DiseaseExtramammaryPagets disease
  35. 35. Miscellaneous TumoursMerkel Cell TumourDermatofibrosarcomaprotruberans (DFSP)
  36. 36. Miscellaneous TumoursMetastatic TumourCutaneous lymphoma

×